专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170239281A1 COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS 审中-公开
公开(公告)号：US20170239281A1
公开(公告)日：2017-08-24
申请号：US15512984
申请日：2015-09-22
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Daniela RAHMEL
IPC分类号： A61K31/70 , A61K31/7034 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K31/496 , A61K31/4045 , A61K31/428 , A61K31/55 , A61K31/40 , A61K31/506 , A61K31/381 , A61K31/48 , A61K31/4985
摘要： The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadreeocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis. polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite.

2. 发明申请

US20200237794A1 TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS 审中-公开
公开(公告)号：US20200237794A1
公开(公告)日：2020-07-30
申请号：US16844522
申请日：2020-04-09
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Nicole MOHREN , Laura JOHNSTON , Bruce SOMERVILLE , Rebecca K. VOTH
IPC分类号： A61K31/7034 , A61K31/351 , A61P3/10 , C07D309/10 , A61P5/50 , A61K31/382 , A61K9/08 , A61K9/02 , A61K9/48 , A61K9/20 , A61K47/02 , A61K31/7056 , A61K31/7048 , A61K31/7042
摘要： One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. For example, the treatment and/or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

3. 发明申请

US20150164856A1 TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS 审中-公开
标题翻译：在动物中治疗代谢性疾病
公开(公告)号：US20150164856A1
公开(公告)日：2015-06-18
申请号：US14573352
申请日：2014-12-17
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Silke HAAG-DIERGARTEN , Leah Jeanette HENNINGS , Saskia KLEY , Anne M. TRAAS
IPC分类号： A61K31/351 , A61K38/28
摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
摘要翻译：本发明涉及用于治疗和/或预防猫科动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式，优选其中代谢紊乱是选自以下的一种或多种：酮症酸中毒，前期糖尿病，1型糖尿病或2型糖尿病，胰岛素抵抗，肥胖症，高血糖症，葡萄糖耐量降低，高胰岛素血症，血脂异常，血管兴奋素血症，亚临床炎症，全身炎症，低度全身炎症，肝脂质变性，动脉粥样硬化，胰腺炎症，神经病和/或综合征X（代谢综合征）和/或胰腺β细胞功能丧失和/或其中代谢紊乱的缓解，优选糖尿病缓解获得和/或维持。

4. 发明申请

US20170087246A1 MODULAR ANTIGEN TRANSPORTATION MOLECULES AND USES THEREOF IN ANIMALS 审中-公开
公开(公告)号：US20170087246A1
公开(公告)日：2017-03-30
申请号：US15276922
申请日：2016-09-27
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Horst ROSE , Dania Birte REICHE , Harald TAMMEN
IPC分类号： A61K39/35 , C07K14/435 , C12N7/00 , C07K14/47
CPC分类号： A61K39/35 , A61K38/00 , A61K39/385 , A61K2039/552 , A61K2039/55505 , A61K2039/575 , A61K2039/577 , A61K2039/622 , C07K7/06 , C07K14/43531 , C07K14/4359 , C07K14/47 , C07K2319/10 , C07K2319/21 , C07K2319/33 , C12N7/00 , C12N2740/16033 , C12N2740/16071
摘要： The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g. for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in animals, more preferably ruminants, pigs, dogs and/or cats, but excluding equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.

5. 发明申请

US20170071969A1 TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS 审中-公开
标题翻译：治疗动物的代谢性疾病
公开(公告)号：US20170071969A1
公开(公告)日：2017-03-16
申请号：US15362031
申请日：2016-11-28
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Laura JOHNSTON , Nicole MOHREN
IPC分类号： A61K31/7034 , A61K47/48 , A61K9/48 , A61K9/02 , A61K9/00 , A61K9/20
CPC分类号： A61K31/7034 , A61K9/0019 , A61K9/0031 , A61K9/0053 , A61K9/02 , A61K9/20 , A61K9/2018 , A61K9/48 , A61K9/4866 , A61K31/70 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K47/545 , C07H15/207
摘要： A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.
摘要翻译：提供SGLT2抑制剂或其药学上可接受的形式用于治疗和/或预防马动物代谢紊乱。特别地，提供SGLT2抑制剂或其药学上可接受的形式用于治疗和/或预防胰岛素抵抗，高胰岛素血症，葡萄糖耐量异常，血脂异常，血管发育不良，血清炎症，全身炎症，低级全身炎症，肥胖症，和/或马类动物中的局部肥胖。

6. 发明申请

US20150272977A1 TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS 审中-公开
标题翻译：治疗动物的代谢性疾病
公开(公告)号：US20150272977A1
公开(公告)日：2015-10-01
申请号：US14672705
申请日：2015-03-30
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Nicole MOHREN , Laura JOHNSTON , Bruce SOMERVILLE , Rebecca K. VOTH
IPC分类号： A61K31/7034 , A61K31/7048 , A61K31/7056 , A61K31/7042
摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
摘要翻译：本发明涉及用于治疗和/或预防马动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式。特别地，本发明涉及一种或多种SGLT2抑制剂或其药学上可接受的形式，其用于治疗和/或预防椎板炎，血管功能障碍，高血压，肝脏脂质沉积，动脉粥样硬化，超肾上腺皮质激素，垂体间叶中间功能障碍和/或马动物中的马代谢综合征。

7. 发明申请

US20230140631A1 TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS 有权
公开(公告)号：US20230140631A1
公开(公告)日：2023-05-04
申请号：US18086830
申请日：2022-12-22
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Silke HAAG-DIERGARTEN , Leah Jeanette HENNINGS , Saskia KLEY , Anne M. TRAAS
IPC分类号： A61K31/351 , A61K38/28 , A61K31/7034 , C07D309/10 , C07H7/04 , A61P3/10 , A61K31/7042 , C07D493/10 , C07D493/08 , A61P3/06 , A61P31/12 , A61K31/357 , A61P9/12 , A61K31/381 , A61K31/7056 , C07H17/02 , C07D335/02 , A61K31/35 , A61K47/22 , C07D333/12 , A61P5/50 , A61P3/04 , C07H17/00 , C07H5/10 , A61P3/00 , C07H15/203 , A61P29/00 , C07D333/56
摘要： One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably where the metabolic disorder is one or more selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or where the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

8. 发明申请

US20210161930A1 USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS 有权
公开(公告)号：US20210161930A1
公开(公告)日：2021-06-03
申请号：US17104414
申请日：2020-11-25
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE
IPC分类号： A61K31/7048 , A61P15/14 , A61K31/351 , A61K31/381 , A23K20/121 , A23K50/10 , A23K20/24
摘要： The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

9. 发明申请

US20210128719A1 MODULAR ANTIGEN TRANSPORTATION MOLECULES AND USES THEREOF IN ANIMALS 有权
公开(公告)号：US20210128719A1
公开(公告)日：2021-05-06
申请号：US17122593
申请日：2020-12-15
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Horst ROSE , Dania Birte REICHE , Harald TAMMEN
IPC分类号： A61K39/35 , A61K39/385 , C07K7/06 , C07K14/435 , C07K14/47 , C12N7/00
摘要： The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g. for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in animals, more preferably ruminants, pigs, dogs and/or cats, but excluding equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.

10. 发明申请

US20210069222A1 TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS 有权
公开(公告)号：US20210069222A1
公开(公告)日：2021-03-11
申请号：US17094591
申请日：2020-11-10
申请人： Boehringer Ingelheim Vetmedica GmbH
发明人： Dania Birte REICHE , Laura JOHNSTON , Nicole MOHREN
IPC分类号： A61K31/7034 , C07H15/207 , A61K9/02 , A61K9/00 , A61K31/7048 , A61K9/20 , A61K31/7056 , A61K31/70 , A61K31/7042 , A61K9/48 , A61K47/54 , A61K31/351 , C07D309/10
摘要： A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式